A. Hardi

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers

Á. Illés, T. Masszi, G. Mikala, 2022, Pathology & Oncology Research.

Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers

Z. Lengyel, Á. Illés, Z. Borbényi, 2021, Pathology & Oncology Research.

Identification of the best‐suited donor for generating virus‐specific T cells

J. Sinko, T. Masszi, P. Reményi, 2020, Vox sanguinis.

Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation

J. Sinko, G. Kriván, M. Réti, 2017, Journal of immunotherapy.

Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime

Á. Illés, T. Masszi, G. Mikala, 2021, Orvosi hetilap.